ET-743 is a product of PharmaMar, a Spanish biopharmaceutical company developing anticancer drugs derived from marine organisms.
Tunicates are sea creatures encased by tough membranes, reminiscent of tunics.
We are pleased that ET-743 has a reasonably favorable safety profile and does not appear to demonstrate cumulative effects. ET-743 interacts with the DNA in tumor cells in a manner different from conventional chemotherapy drugs. This novel mechanism of action may be responsible for the important sustained disease control seen in our trials. The drug is a promising development in the treatment of sarcoma. The trials are assessing the activity of ET-743 in three distinct groups of patients with sarcomas.